Natera, Inc. $NTRA Shares Purchased by Groupama Asset Managment

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Groupama Asset Managment raised its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 48.8% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 81,839 shares of the medical research company's stock after acquiring an additional 26,841 shares during the quarter. Groupama Asset Managment owned approximately 0.06% of Natera worth $11,780,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. LRI Investments LLC purchased a new stake in shares of Natera in the fourth quarter valued at $29,000. Bank of Jackson Hole Trust purchased a new stake in shares of Natera in the first quarter valued at $29,000. Rakuten Securities Inc. grew its position in shares of Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after purchasing an additional 119 shares during the period. ORG Partners LLC purchased a new stake in shares of Natera in the first quarter valued at $32,000. Finally, TCTC Holdings LLC grew its position in shares of Natera by 114.8% in the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock valued at $33,000 after purchasing an additional 124 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Price Performance

NTRA stock traded up $3.65 during trading on Friday, reaching $165.60. 839,847 shares of the stock traded hands, compared to its average volume of 1,637,383. The business's 50 day moving average price is $154.85 and its 200-day moving average price is $154.01. Natera, Inc. has a 52-week low of $110.57 and a 52-week high of $183.00. The firm has a market capitalization of $22.73 billion, a PE ratio of -86.70 and a beta of 1.76.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The company had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company's revenue for the quarter was up 32.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Buying and Selling

In other Natera news, CFO Michael Burkes Brophy sold 3,045 shares of the business's stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total transaction of $418,383.00. Following the transaction, the chief financial officer owned 65,430 shares in the company, valued at $8,990,082. The trade was a 4.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Steven Leonard Chapman sold 6,111 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $157.10, for a total value of $960,038.10. Following the completion of the transaction, the chief executive officer owned 179,071 shares in the company, valued at approximately $28,132,054.10. This trade represents a 3.30% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 61,792 shares of company stock worth $9,227,972. Company insiders own 5.63% of the company's stock.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of recent analyst reports. Evercore ISI raised Natera to a "strong-buy" rating and set a $170.00 price objective for the company in a research report on Monday, July 28th. Cowen reaffirmed a "buy" rating on shares of Natera in a research report on Friday, August 8th. Morgan Stanley reaffirmed an "overweight" rating and issued a $195.00 price objective on shares of Natera in a research report on Sunday, August 10th. Piper Sandler reissued an "overweight" rating and set a $220.00 price target (up previously from $210.00) on shares of Natera in a research report on Monday, August 11th. Finally, Wall Street Zen downgraded Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. One investment analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $193.19.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.